Universal Beteiligungs und Servicegesellschaft mbH Acquires 21,282 Shares of Novavax, Inc. $NVAX

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 138.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 36,689 shares of the biopharmaceutical company’s stock after acquiring an additional 21,282 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Novavax were worth $231,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Signaturefd LLC grew its position in Novavax by 47.2% in the second quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 3,122 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Novavax in the 2nd quarter valued at approximately $73,000. Vise Technologies Inc. bought a new stake in shares of Novavax during the 2nd quarter valued at approximately $70,000. Vanguard Personalized Indexing Management LLC acquired a new position in Novavax during the 2nd quarter worth approximately $72,000. Finally, Kapitalo Investimentos Ltda bought a new position in Novavax in the 2nd quarter valued at approximately $79,000. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Trading Up 1.1%

Shares of NVAX stock opened at $7.02 on Friday. Novavax, Inc. has a 1-year low of $5.01 and a 1-year high of $11.55. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of 3.08, a PEG ratio of 0.12 and a beta of 2.68. The stock has a 50-day moving average of $8.03 and a 200-day moving average of $7.61.

Novavax (NASDAQ:NVAX) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.08) by ($0.17). The company had revenue of $70.45 million during the quarter, compared to the consensus estimate of $55.63 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The business’s revenue was down 16.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.76) earnings per share. Novavax has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NVAX has been the topic of a number of research reports. Bank of America reaffirmed an “underperform” rating and set a $7.00 target price (down previously from $9.00) on shares of Novavax in a research note on Wednesday, August 20th. B. Riley reissued a “buy” rating and set a $16.00 price objective (down previously from $18.00) on shares of Novavax in a report on Monday, November 10th. JPMorgan Chase & Co. lowered their target price on Novavax from $7.00 to $6.00 and set an “underweight” rating for the company in a report on Tuesday, November 18th. HC Wainwright lifted their price target on Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Finally, Cantor Fitzgerald started coverage on Novavax in a report on Friday, October 24th. They set an “overweight” rating and a $18.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $11.25.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.